Comparison of Efficacy and Safety of Standard vs Higher Starting Dose of Insulin Glargine in Overweight and Obese Chinese Patients With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 08 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 26 Jul 2016 Status changed from not yet recruiting to recruiting.